A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m 2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862
Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 851
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Díaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., Reina, J. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8467 · Cited by 268
Köhne, C.-H., De Greve, J., Hartmann, J. T., Lang, I., Vergauwe, P., Becker, K., Braumann, D., Joosens, E., Müller, L., Janssens, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm544 · Cited by 162
Cited by
Efficacy of S-1 in colorectal cancer
Miyamoto, Y., Sakamoto, Y., Yoshida, N., & Baba, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.937706 · Cited by 20
“In addition, several Phase II studies have also been conducted to evaluate the combination chemotherapy with oral fluoropyrimidine S-1 plus irinotecan and bevacizumab therapy [32-35].”
BackgroundSadahiro, S., Suzuki, T., Okada, K., Saito, G., Miyakita, H., Ogimi, T., Chan, L. F., & Kamei, Y. (2020) · Oncology · doi:10.1159/000507293 · Cited by 11
Mizushima, T., Fukunaga, M., Sueda, T., Ikeda, M., Kato, T., Kim, H. M., Kudo, T., Murata, K., Nishimura, J., Hata, T., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3336-3 · Cited by 9
“Moreover, the efficacy of IRIS therapy for advanced or recurrent colorectal cancer, which used in combination with irinotecan and S-1, has been found to be equivalent to FOLFIRI therapy as a first-line treatment [19, 20] and a second-line treatment after oxaliplatin-based chemotherapy [13].”
BackgroundSelf-citationSadahiro, S., Suzuki, T., Tanaka, A., Okada, K., Saito, G., & Kamijo, A. (2015) · Oncology · doi:10.1159/000369976 · Cited by 6
Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70294 · Cited by 5
Metadata
- Authors
- Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Hasegawa, J., Hata, T., Takemasa, I., Ikeda, M., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., Mori, M., & on behalf of the Clinical Study Group of Osaka University (CSGO), C. G.
- Affiliations
- The University of Osaka (JP)
- Suita Municipal Hospital (JP)
- Hannan University (JP)
- Sakai City Medical Center (JP)
- Osaka Prefectural Medical Center (JP)
- Osaka Rosai Hospital (JP)
- Toyonaka Municipal Hospital (JP)
- Osaka National Hospital (JP)
- Nishinomiya Municipal Central Hospital (JP)
- ORCID
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 85
- Issue
- 6
- Pages
- 317-322
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2019831318
- Cited by
- 8
- References
- 18
- Citations by year
- 2024: 1 · 2020: 1 · 2017: 1 · 2015: 2 · 2014: 3
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, S-1, irinotecan, bevacizumab, first-line chemotherapy, combination chemotherapy, response rate, progression-free survival, overall survival, neutropenia, diarrhea
- MeSH terms
- Bevacizumab, Irinotecan, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colonic Neoplasms, Drug Combinations, Female, Tegafur, Humans, Male, Middle Aged, Neoplasm Metastasis, Oxonic Acid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer. https://app.cochat.ai/papers/10.1159/000356018
- The paper
- Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Hasegawa, J., Hata, T., Takemasa, I., Ikeda, M., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., Mori, M., & on behalf of the Clinical Study Group of Osaka University (CSGO), C. G. (2013). A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer. Oncology. https://doi.org/10.1159/000356018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.